Posaconazole (Noxafil)

Posaconazole is a second-generation triazole antifungal agent that represents one of the most advanced options available for treating serious fungal infections in veterinary medicine. Marketed under the brand name Noxafil for human use, posaconazole is used off-label in cats for the treatment of severe, disseminated, or refractory fungal infections that have not responded to first-line antifungal agents. This medication's extended spectrum of activity and ability to achieve therapeutic concentrations in various body tissues make it a valuable option for cats with life-threatening mycoses or infections caused by organisms resistant to other antifungal medications.

The mechanism of action of posaconazole follows the triazole antifungal class mechanism of inhibiting ergosterol synthesis in fungal cell membranes. Posaconazole inhibits the fungal enzyme lanosterol 14-alpha-demethylase (CYP51), which is essential for converting lanosterol to ergosterol. Ergosterol is a critical component of fungal cell membranes, analogous to cholesterol in mammalian cells. By blocking ergosterol production, posaconazole disrupts membrane integrity and permeability, ultimately leading to cell death. Posaconazole demonstrates both fungistatic and fungicidal activity depending on the concentration achieved and the organism involved, with particular potency against Aspergillus species, Mucorales, and many other clinically important fungi.

Posaconazole is available in multiple formulations including an oral suspension, delayed-release tablets, and intravenous solution. The oral suspension and delayed-release tablets have different pharmacokinetic properties, with the delayed-release tablets providing more consistent absorption and higher blood levels compared to the suspension. The intravenous formulation is used when oral administration is not possible or adequate absorption cannot be ensured. In cats, the oral formulations are most commonly used, with dosing and formulation selection guided by veterinary specialists experienced in treating serious fungal infections.

Due to its status as a specialized antifungal agent, posaconazole is typically reserved for cats with serious fungal infections where first-line therapies have failed or are contraindicated, or where the causative organism is known or suspected to be resistant to other antifungals. The use of posaconazole in cats generally occurs under the guidance of veterinary internal medicine specialists or dermatologists with expertise in mycology. The medication carries a higher cost compared to older antifungal agents and requires careful monitoring during treatment. Veterinary supervision is essential for appropriate patient selection, dosing, monitoring for efficacy and adverse effects, and determining treatment duration for these challenging fungal infections.

The primary indication for posaconazole in cats is the treatment of serious, invasive, or refractory fungal infections where other antifungal agents have proven ineffective or cannot be used. Aspergillosis, particularly sinonasal or disseminated forms, represents one of the key infections where posaconazole may be employed. Aspergillus species cause upper respiratory tract infections in cats that can be challenging to treat, and when standard azole therapy with itraconazole fails to achieve resolution, posaconazole provides a more potent alternative with excellent activity against Aspergillus organisms. Disseminated aspergillosis affecting multiple organ systems represents an even more serious condition where posaconazole's extended tissue distribution may be beneficial.

Posaconazole's spectrum of activity includes organisms that cause serious systemic mycoses in cats. Cryptococcosis, caused by Cryptococcus neoformans or Cryptococcus gattii, is one of the most common systemic fungal infections in cats and typically responds to fluconazole or itraconazole therapy. However, when cryptococcal infections prove resistant to first-line treatment, relapse after initial therapy, or affect critical structures such as the central nervous system with inadequate response to standard treatment, posaconazole offers a second-line option. The drug's ability to achieve meaningful concentrations in the brain and central nervous system can be advantageous for treating cryptococcal meningitis.

Histoplasmosis, blastomycosis, and coccidioidomycosis are dimorphic fungal infections that can occur in cats living in or traveling to endemic regions. These infections are typically treated with itraconazole or amphotericin B, but cases that are refractory to standard therapy, recurrent, or occur in cats that cannot tolerate first-line treatments may benefit from posaconazole's broad-spectrum activity. The emerging resistance of some fungal organisms to older azole antifungals has increased interest in posaconazole as a treatment option for various systemic mycoses.

Posaconazole has activity against the Mucorales order of fungi, which cause mucormycosis, a serious and often life-threatening infection. This activity distinguishes posaconazole from many other azole antifungals that have limited effectiveness against these organisms. While mucormycosis is uncommon in cats, when it occurs, treatment options are limited, and posaconazole represents one of the few oral agents with meaningful activity. Sporotrichosis and other rare fungal infections may also be treated with posaconazole when more commonly used agents fail.

Veterinarians select posaconazole for cats when the severity of infection warrants its use, when other antifungal options have been exhausted or proven ineffective, or when the fungal organism identified is known to be susceptible to posaconazole but resistant to other agents. The decision to use posaconazole typically involves consultation with veterinary specialists, as the medication's high cost, requirement for therapeutic drug monitoring in some cases, and potential for adverse effects make it a treatment reserved for carefully selected patients with serious fungal disease.

Dosing of posaconazole in cats is determined by veterinary specialists based on the specific fungal infection being treated, the formulation being used, and individual patient factors. Posaconazole pharmacokinetics have been studied in cats but are less well characterized than in humans, and dosing recommendations continue to evolve as clinical experience accumulates. The veterinarian will calculate an appropriate dose based on current knowledge, the cat's body weight, and the specific circumstances of the infection. Cat owners should never attempt to determine posaconazole dosing independently due to the complexity of treating serious fungal infections and the importance of achieving adequate drug levels.

Posaconazole is available in two oral formulations with different pharmacokinetic profiles that affect dosing. The oral suspension has variable absorption that is significantly enhanced by administration with a high-fat meal, while the delayed-release tablets provide more consistent absorption that is less dependent on food intake. In cats, the oral suspension has been more commonly used due to ease of administration, but the different absorption characteristics must be considered. The veterinarian will specify which formulation to use and provide instructions regarding administration with or without food based on the selected formulation.

Treatment duration with posaconazole for serious systemic fungal infections is typically prolonged, often lasting months to achieve cure. Aspergillosis, cryptococcosis, and other deep mycoses require extended therapy with treatment continuing well beyond resolution of clinical signs to prevent relapse. The veterinarian will determine treatment duration based on clinical response, imaging findings where applicable, serological markers for some infections, and overall patient status. Follow-up appointments are essential for monitoring treatment progress and determining when therapy can be safely discontinued.

Administration of the oral suspension involves measuring the prescribed dose accurately using the provided measuring device. For the suspension formulation, administration with a fatty meal or snack improves absorption and is typically recommended. The suspension should be shaken well before each dose. Delayed-release tablets should be swallowed whole without crushing or splitting, which may be challenging in cats and limits their use in many feline patients. The veterinarian will advise on the best administration approach for the individual cat and the selected formulation.

Missed doses of posaconazole should be given as soon as remembered unless it is nearly time for the next scheduled dose. Maintaining consistent therapeutic drug levels is important for treating serious fungal infections, and missed doses can potentially affect treatment success. The veterinarian may recommend therapeutic drug monitoring to verify that adequate blood levels are being achieved, particularly if response to treatment is not as expected. Doses should never be doubled to make up for missed doses.

Completing the full course of posaconazole treatment is critical for serious fungal infections. Premature discontinuation, even when the cat appears improved, can result in relapse of infection that may be harder to treat the second time due to potential development of drug resistance. The treating veterinarian will guide decisions about treatment duration based on objective measures of treatment response and will advise when it is appropriate to discontinue therapy.

Posaconazole is generally well tolerated in cats when appropriate doses are used and the patient is properly monitored, though adverse effects can occur, particularly with prolonged treatment for serious fungal infections. Because posaconazole is reserved for cats with significant fungal disease, distinguishing drug-related adverse effects from manifestations of the underlying infection can sometimes be challenging. Close veterinary monitoring throughout treatment helps detect and manage any adverse effects that develop.

Gastrointestinal effects are among the most commonly observed side effects of posaconazole in cats. Decreased appetite, nausea, vomiting, or diarrhea may occur during treatment. These effects are often mild and may improve as treatment continues, but persistent gastrointestinal upset should be reported to the veterinarian. For the oral suspension formulation, the vehicle or flavoring may contribute to palatability issues or gastrointestinal effects in some cats. Administering the medication with food when appropriate and other supportive measures can help manage gastrointestinal side effects.

Hepatic effects are a recognized concern with azole antifungal medications, including posaconazole. While posaconazole is generally considered to have a favorable hepatic safety profile compared to some other azoles, elevated liver enzymes can occur during treatment. Regular monitoring of liver enzymes through blood testing is typically recommended during posaconazole therapy to detect hepatic effects early. Signs of liver dysfunction such as jaundice (yellowing of skin, gums, or eyes), dark urine, or worsening lethargy should be reported immediately to the veterinarian.

Other potential adverse effects of posaconazole may include electrolyte disturbances, particularly hypokalemia (low potassium), which can affect muscle and cardiac function. Blood pressure changes and fluid retention have been reported in human patients. Neurological effects including headache and dizziness have been reported in humans but are difficult to assess in cats. Skin reactions are uncommon but possible with any medication. Blood cell abnormalities including changes in white blood cell counts can occur rarely.

Serious adverse effects requiring immediate veterinary attention include signs of severe allergic reaction such as facial swelling, hives, or difficulty breathing, signs of significant liver dysfunction including jaundice, collapse or severe weakness that could indicate electrolyte or cardiac effects, and any sudden worsening of the cat's condition. While serious adverse effects are uncommon, the severity of infections treated with posaconazole and the prolonged treatment courses required mean that vigilant monitoring is essential. Regular veterinary follow-up allows for early detection and management of any adverse effects that develop during treatment.

Posaconazole is contraindicated in cats with known hypersensitivity or previous allergic reactions to posaconazole or other azole antifungal medications. Cats that have experienced severe adverse reactions to related drugs such as itraconazole, fluconazole, ketoconazole, or voriconazole may be at increased risk for similar reactions to posaconazole and should be treated with alternative antifungal agents when possible. Cat owners should inform their veterinarian of any previous adverse reactions to antifungal medications before posaconazole therapy is considered.

Significant liver disease may contraindicate or require cautious use of posaconazole in cats. While posaconazole is considered to have a relatively favorable hepatic safety profile among azole antifungals, pre-existing liver dysfunction increases the risk of drug accumulation and hepatic adverse effects. Cats with elevated liver enzymes, known hepatic insufficiency, or clinical liver disease require careful evaluation of the risks and benefits of posaconazole therapy. If treatment is undertaken in cats with liver compromise, more frequent monitoring of liver function is essential. Alternative antifungal agents with better hepatic safety profiles may be preferred when available and appropriate for the fungal organism involved.

Posaconazole should be avoided in pregnant cats due to potential teratogenic effects. Studies in laboratory animals have demonstrated embryotoxicity and skeletal abnormalities associated with posaconazole exposure during pregnancy, and similar risks are assumed for feline pregnancies. Nursing queens should also avoid posaconazole, as the drug may be excreted in milk and could affect nursing kittens. For pregnant or lactating cats with serious fungal infections, the treating veterinarian will carefully evaluate alternatives and discuss the risks and benefits of treatment options with the cat owner.

Concurrent administration of certain medications is contraindicated or requires extreme caution with posaconazole due to significant drug interactions. Posaconazole is a potent inhibitor of cytochrome P450 enzyme CYP3A4 and can dramatically increase blood levels of drugs metabolized by this pathway. Concurrent use of ergot alkaloids, certain immunosuppressants without dose modification, some cardiac medications, and various other drugs may be contraindicated or require careful management. The veterinarian will review all concurrent medications before initiating posaconazole therapy to identify and manage potential interactions.

Posaconazole has significant drug interaction potential due to its potent inhibition of cytochrome P450 enzyme CYP3A4, which metabolizes many drugs in the body. This inhibition can substantially increase blood levels of medications metabolized by this pathway, potentially leading to toxicity. Cat owners must inform their veterinarian of all medications, supplements, and over-the-counter products their cat is receiving before posaconazole therapy begins. Failure to identify potential interactions can result in serious adverse effects from accumulated medications or reduced efficacy of either drug.

Cyclosporine, used for immune-mediated conditions in cats, is significantly affected by posaconazole's enzyme inhibition. Co-administration can increase cyclosporine blood levels several-fold, requiring substantial dose reduction of cyclosporine to avoid toxicity. Therapeutic drug monitoring of cyclosporine levels is essential when these medications are used together. Similarly, tacrolimus levels can be increased by posaconazole, requiring careful management in cats receiving both drugs. The veterinarian will calculate appropriate dose adjustments based on the specific circumstances.

Benzodiazepines such as midazolam and certain other sedatives can have markedly increased and prolonged effects when administered with posaconazole due to reduced metabolism. This can result in excessive sedation and other adverse effects. Some calcium channel blockers, certain antiparasitic medications, and various other drugs metabolized by CYP3A4 may also have increased levels when used with posaconazole. The veterinarian will review all concurrent medications for potential interactions and make appropriate adjustments or alternative selections.

Medications that induce cytochrome P450 enzymes can reduce posaconazole blood levels, potentially leading to treatment failure for serious fungal infections. Rifampin, phenobarbital, and certain other enzyme-inducing drugs should be avoided during posaconazole therapy when possible. Medications that reduce stomach acid, particularly proton pump inhibitors such as omeprazole, can significantly decrease absorption of posaconazole oral suspension, though this effect is less pronounced with the delayed-release tablet formulation. The timing of acid-reducing medications relative to posaconazole and the choice of formulation should be discussed with the veterinarian. Regular veterinary follow-up and potential therapeutic drug monitoring help ensure that posaconazole maintains therapeutic levels despite potential interactions.

General precautions for posaconazole use in cats emphasize the importance of accurate diagnosis and appropriate patient selection for this specialized antifungal agent. Posaconazole should be reserved for serious fungal infections where its specific activity is needed, rather than used empirically for routine fungal conditions. Culture and identification of the causative fungal organism, along with susceptibility testing when available, helps confirm that posaconazole is appropriate for the infection being treated. The decision to use posaconazole typically involves consultation with veterinary specialists experienced in treating mycoses.

Regular monitoring during posaconazole treatment is essential due to the prolonged treatment courses required and potential for adverse effects. Baseline bloodwork including complete blood count and serum chemistry with liver enzymes should be performed before initiating therapy, with repeat testing at regular intervals during treatment. The frequency of monitoring depends on the individual patient's health status and response to treatment, with more frequent testing during initial therapy and for cats with any abnormalities. Therapeutic drug monitoring may be recommended in some cases to verify adequate blood levels are achieved.

Environmental considerations for posaconazole include proper handling of the medication and awareness of its potent pharmacological activity. The medication should be handled carefully, and pregnant women should avoid handling posaconazole due to potential teratogenic effects. In multi-cat households, only the prescribed cat should receive the medication, and it should be stored securely to prevent accidental access by other animals. Proper disposal of unused medication follows guidelines for prescription drug disposal.

Monitoring the cat's clinical response to treatment is an important component of posaconazole therapy. Signs of improvement in the fungal infection, including resolution of respiratory signs, improvement in skin lesions, weight gain, and increased activity, should be documented. Regular veterinary examinations, imaging studies for internal infections, and serological monitoring where applicable help assess treatment efficacy. Any signs of adverse effects including decreased appetite, vomiting, jaundice, lethargy, or other concerning changes should be reported promptly.

Special population considerations for posaconazole include increased caution in geriatric cats, who may have age-related decreases in organ function affecting drug metabolism and elimination. Cats with renal impairment may require modified approaches, as the intravenous formulation contains a cyclodextrin vehicle that accumulates in renal dysfunction. Young cats and kittens have limited published information regarding posaconazole safety and dosing, and treatment in this age group requires careful veterinary judgment. The treating veterinarian will determine appropriate monitoring protocols and adjust therapy based on individual patient factors and response to treatment.

Posaconazole oral suspension should be stored at controlled room temperature, typically between 59 and 77 degrees Fahrenheit (15 to 25 degrees Celsius), and should not be frozen. The container should be kept tightly closed when not in use to prevent contamination and maintain medication stability. The suspension should be shaken well before each use to ensure uniform distribution of the medication. Storage should be away from heat sources and direct light. The medication should be kept in its original container, which is designed to protect the contents from degradation.

Posaconazole delayed-release tablets should also be stored at room temperature, protected from moisture. The tablets should remain in their original packaging until use, as the blister packaging protects against moisture that could affect the delayed-release coating. Once removed from the blister pack, tablets should be used promptly. Both formulations should be checked for expiration dates, and expired medication should not be used, as potency and safety cannot be guaranteed beyond the expiration date.

Safe handling of posaconazole requires keeping the medication out of reach of children and other pets. Accidental ingestion by humans or animals could cause adverse effects, and significant exposures require medical or veterinary attention. Pregnant women should avoid handling posaconazole due to the medication's teratogenic potential. When administering the oral suspension, the provided measuring device should be used for accurate dosing, and any spills should be cleaned promptly. Hands should be washed after handling the medication.

Disposal of unused or expired posaconazole should follow guidelines for prescription medication disposal. Drug take-back programs represent the preferred disposal method when available, as they ensure environmentally responsible disposal of potent medications. If take-back programs are not available, the FDA recommends mixing medications with undesirable substances such as used coffee grounds or cat litter, placing in a sealed container, and disposing in household trash. Posaconazole should not be flushed down toilets or poured down drains. Due to the high cost of posaconazole, cat owners should discuss with their veterinarian the appropriate amount to obtain, as extended treatment courses may require multiple refills while initial response to treatment is being assessed.

Posaconazole can be used in cats of all breeds when indicated for serious systemic fungal infections, with no breed-specific contraindications or documented variations in sensitivity to this medication. The serious nature of infections typically treated with posaconazole means that treatment decisions are based on the specific fungal disease, patient health status, and response to other therapies rather than breed considerations. All cat breeds can potentially benefit from posaconazole therapy when appropriate for their fungal infection.

Certain feline populations may be more likely to develop the serious fungal infections for which posaconazole is used. Cats living outdoors, in rural areas, or in geographic regions endemic for specific fungi may have higher exposure to fungal organisms causing systemic mycoses. Immunocompromised cats, including those with feline immunodeficiency virus (FIV), feline leukemia virus (FeLV), or receiving immunosuppressive therapy, are at increased risk for serious or invasive fungal infections that may require advanced antifungal therapy. These risk factors cross all breed lines and relate more to lifestyle and health status than genetics.

Size variations among cat breeds affect dosing calculations but do not change posaconazole's safety or efficacy profile. Larger breeds such as Maine Coons receive larger total doses based on their greater body weight, while smaller cats require careful dose calculation. Accurate weighing and dose calculation are important for all cats receiving posaconazole to ensure adequate therapeutic levels are achieved for treating serious infections. The veterinarian will determine appropriate dosing based on current pharmacokinetic information and the individual cat's weight and condition.

Age considerations apply across all cat breeds when using posaconazole. Young kittens have limited information available regarding posaconazole use, and treatment in very young cats requires careful veterinary judgment weighing the severity of infection against limited safety data. Geriatric cats may have age-related changes in liver and kidney function that affect drug metabolism and elimination, potentially requiring modified dosing or more frequent monitoring. The treating veterinary specialist will consider individual patient factors when prescribing posaconazole, tailoring the treatment approach to the specific cat's needs, fungal infection, and overall health status rather than breed characteristics.

Several other systemic antifungal medications serve as first-line alternatives to posaconazole for treating fungal infections in cats. Itraconazole (Sporanox, Itrafungol) is the most commonly used systemic antifungal in feline medicine, with established efficacy against dermatophytes, cryptococcosis, blastomycosis, histoplasmosis, and many other fungal infections. Itraconazole is typically tried before posaconazole for most fungal conditions. Fluconazole (Diflucan) is another triazole antifungal with excellent bioavailability and central nervous system penetration, making it particularly valuable for cryptococcal meningitis and other CNS fungal infections. Fluconazole is often a first-line choice for cryptococcosis and some other systemic mycoses.

For refractory or severe infections not responding to standard azole therapy, options include posaconazole as well as voriconazole, another extended-spectrum triazole with activity against Aspergillus and other fungi. Amphotericin B remains an important option for life-threatening fungal infections, though its nephrotoxicity and requirement for intravenous administration limit its use to severe cases requiring hospitalization. Lipid-complexed formulations of amphotericin B (such as AmBisome) have reduced nephrotoxicity compared to conventional amphotericin B. Terbinafine, while primarily used for dermatophytosis, may be combined with azole antifungals for some systemic infections.

Complementary approaches to treating serious fungal infections include supportive care to maintain patient strength and immune function during prolonged treatment courses. Nutritional support, management of concurrent conditions, and appropriate monitoring all contribute to treatment success. Surgical intervention may be necessary for some fungal infections, particularly localized aspergillosis or masses caused by fungal organisms. The selection of antifungal therapy is guided by the specific fungal organism identified, the location and severity of infection, the cat's overall health status, and response to previous treatments. Treatment decisions for serious mycoses should involve veterinary specialists with expertise in managing these challenging infections.